NCT06305728

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

Immuno-Positron Emission Tomography, Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 25 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts: * The ImmunoPET scan (immune-positron emission tomography scan) with the imaging agent 89Zr-DFO-HuMab-5B1 * The HP MRI scan (hyperpolarized pyruvate magnetic resonance imaging scan)

Conditions

• Pancreatic Cyst

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	89Zr-DFO-HuMab-5B1 immunoPET	Participants who choose to will undergo immunoPET before surgery.
DIAGNOSTIC_TEST	HP MRI	Participants who choose to will undergo HP MRI before surgery.
COMBINATION_PRODUCT	Blood assay	Will be drawn within 6 weeks of surgery and annually as post operative care

Timeline

• Start date: 2024-03-04
• Primary completion: 2030-03-04
• Completion: 2030-03-04
• First posted: 2024-03-12
• Last updated: 2025-10-09

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study